Charting the next chapter: IFFIm launches strategic review ahead of its 20th anniversary
Charting the next chapter: IFFIm launches strategic review ahead of its 20th anniversary
25 March 2026
Angola introduced its first-ever HPV campaign in 2025. Gavi/2025/Wilson Photographer
The review focuses on IFFIm’s continuing role as financing partner for global immunisation in the years ahead.
Announcements
Gavi/2025/Wilson Photographer
As IFFIm approaches its 20th anniversary in 2026 and Gavi enters its Gavi 6.0 strategic period, the organisation, in a joint initiative between the IFFIm Board and the Gavi Secretariat, has embarked on a strategic review to ensure it remains a powerful and relevant financing partner for global immunisation in the decade ahead. The development finance landscape has shifted significantly in recent years, with heightened expectations for institutions to do more with less. This moment presents a natural inflection point for IFFIm to reflect, adapt and position itself for continued impact. It also reflects a forward-looking collaboration among IFFIm, Gavi and IFFIm’s donors that was developed during constructive discussions during the recent replenishment.
The goal of the strategic review is to determine the most flexible, efficient and value-adding approach for the next era of IFFIm’s work.
Initiated in autumn 2025, the strategic review aims to identify opportunities to optimise IFFIm’s structure, governance and financial market positioning. The goal: to determine the most flexible, efficient and value-adding approach for the next era of IFFIm’s work.
The review is guided by three central objectives:
- Strengthening strategic alignment with IFFIm’s mission and Gavi’s evolving priorities for 2026-2030 and beyond, including a heightened global focus on pandemic readiness and rapid response capabilities.
- Assessing IFFIm’s credit and structural resilience in a changing aid-financing environment, as traditional funding models shift and capital market conditions evolve.
- Exploring enhancements to efficiency and agility, ensuring that IFFIm can best serve both sovereign donors and Gavi’s future needs while maintaining its reputation for innovation and financial excellence.
Engaging donors and partners
A cornerstone of the review is meaningful engagement with IFFIm’s stakeholders. Donor governments, the long-standing champions of innovative finance, are being consulted to deepen understanding of their priorities, constraints and expectations.
These conversations will help shape models that are responsive, realistic and mutually reinforcing.
Gavi/2024/Khasar Sandag
IFFIm is also engaging implementing partners to explore how IFFIm’s comparative advantages can evolve to ensure they remain fit for purpose at a time when concessional finance, global health security and climate-health intersections are rapidly transforming. Their perspectives will help ensure any future model remains rooted in real operational needs.
Independent expertise guiding the process
Following a Gavi-managed competitive procurement process, IFFIm selected an experienced independent consultant to lead the review. The procurement panel included IFFIm Board members and Gavi Secretariat staff, reflecting the close collaboration that will underpin the review’s success.
The strategic review is moving forward through a process that culminates with the presentation of final recommendations and a forward-looking roadmap to the Board. Together, these steps will produce a framework that will guide IFFIm’s long-term strategic direction and help shape the next generation of innovative financing for global immunisation.
Looking ahead to IFFIm’s next 20 years
As the world faces rising financial pressures, shifting donor dynamics and increasingly frequent global health threats, IFFIm’s role as a flexible, frontloaded financing mechanism remains highly valuable.
IFFIm’s role as a flexible, front-loaded financing mechanism remains highly valuable.
This strategic review is an opportunity not only to honour IFFIm’s first two decades – during which more than US$ 10 billion has been raised on the capital markets – but to ensure the organisation remains at the cutting edge of development finance and global health impact.
The year ahead will be pivotal. Through thoughtful analysis, inclusive engagement and a commitment to innovation, IFFIm is preparing to enter its next chapter stronger, more agile and better aligned than ever with the needs of children and communities worldwide.
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.